Inc. (NASDAQ:INCR) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
99.1 Press Release dated November 16, 2020.
Net Element, Inc. Exhibit
EX-99.1 2 ex_202729.htm EXHIBIT 99.1 ex_164748.htm Exhibit 99.1 Net Element Reports Third Quarter 2020 Financial Results MIAMI,…
To view the full exhibit click
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.